PubMed:33163895 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":1199,"end":1214},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma49893"}],"text":"The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.\nObjective: To systematically review the literature and estimate the risk of Chloroquine (CQ) and hydroxychloroquine (HCQ) cardiac toxicity in COVID-19 patients.\nMethods: We searched multiple data sources including PubMed/MEDLINE, Ovid Embase, Ovid EBM Reviews, Scopus, and Web of Science, and medrxiv.org from November 2019 through May 27, 2020. We included studies that enrolled COVID-19 patients treated with CQ or HCQ, with or without azithromycin and reported on cardiac toxicities. We performed a meta-analysis using the arcsine transformation of the different incidences.\nResults: A total of 19 studies with a total of 5652 patients were included. The pooled incidence of TdP arrhythmia or VT or cardiac arrest was 3 per 1000, 95% CI (0-21), I2=96%, 18 studies with 3725 patients. Among 13 studies of 4334 patients, the pooled incidence of discontinuation of CQ or HCQ due to prolonged QTc or arrhythmias was 5%, 95% CI (1-11), I2=98%. The pooled incidence of change in QTc from baseline of ≥ 60 ms or QTc ≥ 500 ms was 9%, 95% CI (3-17), I2=97%. Mean/median age, coronary artery disease, hypertension, diabetes, concomitant QT prolonging medications, ICU care, and severity of illness in the study populations explained between-studies heterogeneity.\nConclusions: Treatment of COVID-19 patients with CQ or HCQ is associated with a significant risk of drug-induced QT prolongation and relatively higher incidence of TdP/VT/cardiac arrest. Therefore, these agents should not be used routinely in the management of COVID-19 disease. COVID-19 patients who are treated with antimalarials for other indications should be adequately monitored."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":1199,"end":1214},"obj":"Body_part"},{"id":"T2","span":{"begin":1208,"end":1214},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0001621"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0001637"}],"text":"The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.\nObjective: To systematically review the literature and estimate the risk of Chloroquine (CQ) and hydroxychloroquine (HCQ) cardiac toxicity in COVID-19 patients.\nMethods: We searched multiple data sources including PubMed/MEDLINE, Ovid Embase, Ovid EBM Reviews, Scopus, and Web of Science, and medrxiv.org from November 2019 through May 27, 2020. We included studies that enrolled COVID-19 patients treated with CQ or HCQ, with or without azithromycin and reported on cardiac toxicities. We performed a meta-analysis using the arcsine transformation of the different incidences.\nResults: A total of 19 studies with a total of 5652 patients were included. The pooled incidence of TdP arrhythmia or VT or cardiac arrest was 3 per 1000, 95% CI (0-21), I2=96%, 18 studies with 3725 patients. Among 13 studies of 4334 patients, the pooled incidence of discontinuation of CQ or HCQ due to prolonged QTc or arrhythmias was 5%, 95% CI (1-11), I2=98%. The pooled incidence of change in QTc from baseline of ≥ 60 ms or QTc ≥ 500 ms was 9%, 95% CI (3-17), I2=97%. Mean/median age, coronary artery disease, hypertension, diabetes, concomitant QT prolonging medications, ICU care, and severity of illness in the study populations explained between-studies heterogeneity.\nConclusions: Treatment of COVID-19 patients with CQ or HCQ is associated with a significant risk of drug-induced QT prolongation and relatively higher incidence of TdP/VT/cardiac arrest. Therefore, these agents should not be used routinely in the management of COVID-19 disease. COVID-19 patients who are treated with antimalarials for other indications should be adequately monitored."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":61,"end":69},"obj":"Disease"},{"id":"T2","span":{"begin":272,"end":280},"obj":"Disease"},{"id":"T3","span":{"begin":378,"end":381},"obj":"Disease"},{"id":"T4","span":{"begin":510,"end":518},"obj":"Disease"},{"id":"T5","span":{"begin":812,"end":822},"obj":"Disease"},{"id":"T6","span":{"begin":832,"end":846},"obj":"Disease"},{"id":"T7","span":{"begin":1029,"end":1040},"obj":"Disease"},{"id":"T8","span":{"begin":1199,"end":1222},"obj":"Disease"},{"id":"T9","span":{"begin":1208,"end":1222},"obj":"Disease"},{"id":"T10","span":{"begin":1224,"end":1236},"obj":"Disease"},{"id":"T11","span":{"begin":1238,"end":1246},"obj":"Disease"},{"id":"T12","span":{"begin":1413,"end":1421},"obj":"Disease"},{"id":"T13","span":{"begin":1558,"end":1572},"obj":"Disease"},{"id":"T14","span":{"begin":1648,"end":1656},"obj":"Disease"},{"id":"T15","span":{"begin":1666,"end":1674},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0010540"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0007263"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0000745"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0007263"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005010"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0000473"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0000745"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.\nObjective: To systematically review the literature and estimate the risk of Chloroquine (CQ) and hydroxychloroquine (HCQ) cardiac toxicity in COVID-19 patients.\nMethods: We searched multiple data sources including PubMed/MEDLINE, Ovid Embase, Ovid EBM Reviews, Scopus, and Web of Science, and medrxiv.org from November 2019 through May 27, 2020. We included studies that enrolled COVID-19 patients treated with CQ or HCQ, with or without azithromycin and reported on cardiac toxicities. We performed a meta-analysis using the arcsine transformation of the different incidences.\nResults: A total of 19 studies with a total of 5652 patients were included. The pooled incidence of TdP arrhythmia or VT or cardiac arrest was 3 per 1000, 95% CI (0-21), I2=96%, 18 studies with 3725 patients. Among 13 studies of 4334 patients, the pooled incidence of discontinuation of CQ or HCQ due to prolonged QTc or arrhythmias was 5%, 95% CI (1-11), I2=98%. The pooled incidence of change in QTc from baseline of ≥ 60 ms or QTc ≥ 500 ms was 9%, 95% CI (3-17), I2=97%. Mean/median age, coronary artery disease, hypertension, diabetes, concomitant QT prolonging medications, ICU care, and severity of illness in the study populations explained between-studies heterogeneity.\nConclusions: Treatment of COVID-19 patients with CQ or HCQ is associated with a significant risk of drug-induced QT prolongation and relatively higher incidence of TdP/VT/cardiac arrest. Therefore, these agents should not be used routinely in the management of COVID-19 disease. COVID-19 patients who are treated with antimalarials for other indications should be adequately monitored."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":80,"end":81},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T2","span":{"begin":130,"end":139},"obj":"http://purl.obolibrary.org/obo/BFO_0000030"},{"id":"T3","span":{"begin":466,"end":468},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T4","span":{"begin":630,"end":631},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T5","span":{"begin":717,"end":718},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T6","span":{"begin":744,"end":745},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T7","span":{"begin":886,"end":888},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T8","span":{"begin":1059,"end":1061},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T9","span":{"begin":1132,"end":1134},"obj":"http://purl.obolibrary.org/obo/CLO_0007874"},{"id":"T10","span":{"begin":1148,"end":1150},"obj":"http://purl.obolibrary.org/obo/CLO_0007874"},{"id":"T11","span":{"begin":1208,"end":1214},"obj":"http://purl.obolibrary.org/obo/UBERON_0001637"},{"id":"T12","span":{"begin":1208,"end":1214},"obj":"http://www.ebi.ac.uk/efo/EFO_0000814"},{"id":"T13","span":{"begin":1465,"end":1466},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.\nObjective: To systematically review the literature and estimate the risk of Chloroquine (CQ) and hydroxychloroquine (HCQ) cardiac toxicity in COVID-19 patients.\nMethods: We searched multiple data sources including PubMed/MEDLINE, Ovid Embase, Ovid EBM Reviews, Scopus, and Web of Science, and medrxiv.org from November 2019 through May 27, 2020. We included studies that enrolled COVID-19 patients treated with CQ or HCQ, with or without azithromycin and reported on cardiac toxicities. We performed a meta-analysis using the arcsine transformation of the different incidences.\nResults: A total of 19 studies with a total of 5652 patients were included. The pooled incidence of TdP arrhythmia or VT or cardiac arrest was 3 per 1000, 95% CI (0-21), I2=96%, 18 studies with 3725 patients. Among 13 studies of 4334 patients, the pooled incidence of discontinuation of CQ or HCQ due to prolonged QTc or arrhythmias was 5%, 95% CI (1-11), I2=98%. The pooled incidence of change in QTc from baseline of ≥ 60 ms or QTc ≥ 500 ms was 9%, 95% CI (3-17), I2=97%. Mean/median age, coronary artery disease, hypertension, diabetes, concomitant QT prolonging medications, ICU care, and severity of illness in the study populations explained between-studies heterogeneity.\nConclusions: Treatment of COVID-19 patients with CQ or HCQ is associated with a significant risk of drug-induced QT prolongation and relatively higher incidence of TdP/VT/cardiac arrest. Therefore, these agents should not be used routinely in the management of COVID-19 disease. COVID-19 patients who are treated with antimalarials for other indications should be adequately monitored."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":24,"end":35},"obj":"Chemical"},{"id":"T2","span":{"begin":206,"end":217},"obj":"Chemical"},{"id":"T3","span":{"begin":219,"end":221},"obj":"Chemical"},{"id":"T4","span":{"begin":227,"end":245},"obj":"Chemical"},{"id":"T5","span":{"begin":541,"end":543},"obj":"Chemical"},{"id":"T6","span":{"begin":568,"end":580},"obj":"Chemical"},{"id":"T7","span":{"begin":826,"end":828},"obj":"Chemical"},{"id":"T8","span":{"begin":878,"end":880},"obj":"Chemical"},{"id":"T9","span":{"begin":995,"end":997},"obj":"Chemical"},{"id":"T10","span":{"begin":1064,"end":1066},"obj":"Chemical"},{"id":"T11","span":{"begin":1174,"end":1176},"obj":"Chemical"},{"id":"T12","span":{"begin":1436,"end":1438},"obj":"Chemical"},{"id":"T13","span":{"begin":1487,"end":1491},"obj":"Chemical"},{"id":"T14","span":{"begin":1555,"end":1557},"obj":"Chemical"},{"id":"T15","span":{"begin":1705,"end":1718},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_90330"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_17606"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_17606"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_17606"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_90330"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_38068"}],"text":"The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.\nObjective: To systematically review the literature and estimate the risk of Chloroquine (CQ) and hydroxychloroquine (HCQ) cardiac toxicity in COVID-19 patients.\nMethods: We searched multiple data sources including PubMed/MEDLINE, Ovid Embase, Ovid EBM Reviews, Scopus, and Web of Science, and medrxiv.org from November 2019 through May 27, 2020. We included studies that enrolled COVID-19 patients treated with CQ or HCQ, with or without azithromycin and reported on cardiac toxicities. We performed a meta-analysis using the arcsine transformation of the different incidences.\nResults: A total of 19 studies with a total of 5652 patients were included. The pooled incidence of TdP arrhythmia or VT or cardiac arrest was 3 per 1000, 95% CI (0-21), I2=96%, 18 studies with 3725 patients. Among 13 studies of 4334 patients, the pooled incidence of discontinuation of CQ or HCQ due to prolonged QTc or arrhythmias was 5%, 95% CI (1-11), I2=98%. The pooled incidence of change in QTc from baseline of ≥ 60 ms or QTc ≥ 500 ms was 9%, 95% CI (3-17), I2=97%. Mean/median age, coronary artery disease, hypertension, diabetes, concomitant QT prolonging medications, ICU care, and severity of illness in the study populations explained between-studies heterogeneity.\nConclusions: Treatment of COVID-19 patients with CQ or HCQ is associated with a significant risk of drug-induced QT prolongation and relatively higher incidence of TdP/VT/cardiac arrest. Therefore, these agents should not be used routinely in the management of COVID-19 disease. COVID-19 patients who are treated with antimalarials for other indications should be adequately monitored."}

{"project":"LitCovid-PubTator","denotations":[{"id":"5","span":{"begin":4,"end":20},"obj":"Disease"},{"id":"6","span":{"begin":24,"end":35},"obj":"Chemical"},{"id":"7","span":{"begin":39,"end":57},"obj":"Chemical"},{"id":"8","span":{"begin":61,"end":69},"obj":"Disease"},{"id":"9","span":{"begin":70,"end":78},"obj":"Species"},{"id":"46","span":{"begin":206,"end":217},"obj":"Chemical"},{"id":"47","span":{"begin":219,"end":221},"obj":"Chemical"},{"id":"48","span":{"begin":227,"end":245},"obj":"Chemical"},{"id":"49","span":{"begin":247,"end":250},"obj":"Chemical"},{"id":"50","span":{"begin":260,"end":268},"obj":"Disease"},{"id":"51","span":{"begin":272,"end":280},"obj":"Disease"},{"id":"52","span":{"begin":281,"end":289},"obj":"Species"},{"id":"53","span":{"begin":510,"end":518},"obj":"Disease"},{"id":"54","span":{"begin":519,"end":527},"obj":"Species"},{"id":"55","span":{"begin":541,"end":543},"obj":"Chemical"},{"id":"56","span":{"begin":547,"end":550},"obj":"Chemical"},{"id":"57","span":{"begin":568,"end":580},"obj":"Chemical"},{"id":"58","span":{"begin":597,"end":615},"obj":"Disease"},{"id":"59","span":{"begin":760,"end":768},"obj":"Species"},{"id":"60","span":{"begin":808,"end":822},"obj":"Disease"},{"id":"61","span":{"begin":826,"end":828},"obj":"Disease"},{"id":"62","span":{"begin":832,"end":846},"obj":"Disease"},{"id":"63","span":{"begin":907,"end":915},"obj":"Species"},{"id":"64","span":{"begin":942,"end":950},"obj":"Species"},{"id":"65","span":{"begin":995,"end":997},"obj":"Chemical"},{"id":"66","span":{"begin":1001,"end":1004},"obj":"Chemical"},{"id":"67","span":{"begin":1029,"end":1040},"obj":"Disease"},{"id":"68","span":{"begin":1199,"end":1222},"obj":"Disease"},{"id":"69","span":{"begin":1224,"end":1236},"obj":"Disease"},{"id":"70","span":{"begin":1238,"end":1246},"obj":"Disease"},{"id":"71","span":{"begin":1413,"end":1421},"obj":"Disease"},{"id":"72","span":{"begin":1422,"end":1430},"obj":"Species"},{"id":"73","span":{"begin":1436,"end":1438},"obj":"Chemical"},{"id":"74","span":{"begin":1442,"end":1445},"obj":"Chemical"},{"id":"75","span":{"begin":1500,"end":1515},"obj":"Disease"},{"id":"76","span":{"begin":1551,"end":1554},"obj":"Disease"},{"id":"77","span":{"begin":1555,"end":1557},"obj":"Disease"},{"id":"78","span":{"begin":1558,"end":1572},"obj":"Disease"},{"id":"79","span":{"begin":1648,"end":1656},"obj":"Disease"},{"id":"80","span":{"begin":1666,"end":1674},"obj":"Disease"},{"id":"81","span":{"begin":1675,"end":1683},"obj":"Species"}],"attributes":[{"id":"A5","pred":"tao:has_database_id","subj":"5","obj":"MESH:D066126"},{"id":"A6","pred":"tao:has_database_id","subj":"6","obj":"MESH:D002738"},{"id":"A7","pred":"tao:has_database_id","subj":"7","obj":"MESH:D006886"},{"id":"A8","pred":"tao:has_database_id","subj":"8","obj":"MESH:C000657245"},{"id":"A9","pred":"tao:has_database_id","subj":"9","obj":"Tax:9606"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"MESH:D002738"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"MESH:D002738"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"MESH:D006886"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"MESH:D006886"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"MESH:D064420"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"MESH:C000657245"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"Tax:9606"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"MESH:C000657245"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"Tax:9606"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"MESH:D002738"},{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"MESH:D006886"},{"id":"A57","pred":"tao:has_database_id","subj":"57","obj":"MESH:D017963"},{"id":"A58","pred":"tao:has_database_id","subj":"58","obj":"MESH:D066126"},{"id":"A59","pred":"tao:has_database_id","subj":"59","obj":"Tax:9606"},{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"MESH:D001145"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"MESH:D017180"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"MESH:D006323"},{"id":"A63","pred":"tao:has_database_id","subj":"63","obj":"Tax:9606"},{"id":"A64","pred":"tao:has_database_id","subj":"64","obj":"Tax:9606"},{"id":"A65","pred":"tao:has_database_id","subj":"65","obj":"MESH:D002738"},{"id":"A66","pred":"tao:has_database_id","subj":"66","obj":"MESH:D006886"},{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"MESH:D001145"},{"id":"A68","pred":"tao:has_database_id","subj":"68","obj":"MESH:D003324"},{"id":"A69","pred":"tao:has_database_id","subj":"69","obj":"MESH:D006973"},{"id":"A70","pred":"tao:has_database_id","subj":"70","obj":"MESH:D003920"},{"id":"A71","pred":"tao:has_database_id","subj":"71","obj":"MESH:C000657245"},{"id":"A72","pred":"tao:has_database_id","subj":"72","obj":"Tax:9606"},{"id":"A73","pred":"tao:has_database_id","subj":"73","obj":"MESH:D002738"},{"id":"A74","pred":"tao:has_database_id","subj":"74","obj":"MESH:D006886"},{"id":"A75","pred":"tao:has_database_id","subj":"75","obj":"MESH:D008133"},{"id":"A76","pred":"tao:has_database_id","subj":"76","obj":"MESH:D016171"},{"id":"A77","pred":"tao:has_database_id","subj":"77","obj":"MESH:D017180"},{"id":"A78","pred":"tao:has_database_id","subj":"78","obj":"MESH:D006323"},{"id":"A79","pred":"tao:has_database_id","subj":"79","obj":"MESH:C000657245"},{"id":"A80","pred":"tao:has_database_id","subj":"80","obj":"MESH:C000657245"},{"id":"A81","pred":"tao:has_database_id","subj":"81","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.\nObjective: To systematically review the literature and estimate the risk of Chloroquine (CQ) and hydroxychloroquine (HCQ) cardiac toxicity in COVID-19 patients.\nMethods: We searched multiple data sources including PubMed/MEDLINE, Ovid Embase, Ovid EBM Reviews, Scopus, and Web of Science, and medrxiv.org from November 2019 through May 27, 2020. We included studies that enrolled COVID-19 patients treated with CQ or HCQ, with or without azithromycin and reported on cardiac toxicities. We performed a meta-analysis using the arcsine transformation of the different incidences.\nResults: A total of 19 studies with a total of 5652 patients were included. The pooled incidence of TdP arrhythmia or VT or cardiac arrest was 3 per 1000, 95% CI (0-21), I2=96%, 18 studies with 3725 patients. Among 13 studies of 4334 patients, the pooled incidence of discontinuation of CQ or HCQ due to prolonged QTc or arrhythmias was 5%, 95% CI (1-11), I2=98%. The pooled incidence of change in QTc from baseline of ≥ 60 ms or QTc ≥ 500 ms was 9%, 95% CI (3-17), I2=97%. Mean/median age, coronary artery disease, hypertension, diabetes, concomitant QT prolonging medications, ICU care, and severity of illness in the study populations explained between-studies heterogeneity.\nConclusions: Treatment of COVID-19 patients with CQ or HCQ is associated with a significant risk of drug-induced QT prolongation and relatively higher incidence of TdP/VT/cardiac arrest. Therefore, these agents should not be used routinely in the management of COVID-19 disease. COVID-19 patients who are treated with antimalarials for other indications should be adequately monitored."}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":79},"obj":"Sentence"},{"id":"T2","span":{"begin":80,"end":129},"obj":"Sentence"},{"id":"T3","span":{"begin":130,"end":140},"obj":"Sentence"},{"id":"T4","span":{"begin":141,"end":290},"obj":"Sentence"},{"id":"T5","span":{"begin":291,"end":299},"obj":"Sentence"},{"id":"T6","span":{"begin":300,"end":475},"obj":"Sentence"},{"id":"T7","span":{"begin":476,"end":616},"obj":"Sentence"},{"id":"T8","span":{"begin":617,"end":707},"obj":"Sentence"},{"id":"T9","span":{"begin":708,"end":716},"obj":"Sentence"},{"id":"T10","span":{"begin":717,"end":783},"obj":"Sentence"},{"id":"T11","span":{"begin":784,"end":916},"obj":"Sentence"},{"id":"T12","span":{"begin":917,"end":1071},"obj":"Sentence"},{"id":"T13","span":{"begin":1072,"end":1181},"obj":"Sentence"},{"id":"T14","span":{"begin":1182,"end":1386},"obj":"Sentence"},{"id":"T15","span":{"begin":1387,"end":1399},"obj":"Sentence"},{"id":"T16","span":{"begin":1400,"end":1573},"obj":"Sentence"},{"id":"T17","span":{"begin":1574,"end":1665},"obj":"Sentence"},{"id":"T18","span":{"begin":1666,"end":1772},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.\nObjective: To systematically review the literature and estimate the risk of Chloroquine (CQ) and hydroxychloroquine (HCQ) cardiac toxicity in COVID-19 patients.\nMethods: We searched multiple data sources including PubMed/MEDLINE, Ovid Embase, Ovid EBM Reviews, Scopus, and Web of Science, and medrxiv.org from November 2019 through May 27, 2020. We included studies that enrolled COVID-19 patients treated with CQ or HCQ, with or without azithromycin and reported on cardiac toxicities. We performed a meta-analysis using the arcsine transformation of the different incidences.\nResults: A total of 19 studies with a total of 5652 patients were included. The pooled incidence of TdP arrhythmia or VT or cardiac arrest was 3 per 1000, 95% CI (0-21), I2=96%, 18 studies with 3725 patients. Among 13 studies of 4334 patients, the pooled incidence of discontinuation of CQ or HCQ due to prolonged QTc or arrhythmias was 5%, 95% CI (1-11), I2=98%. The pooled incidence of change in QTc from baseline of ≥ 60 ms or QTc ≥ 500 ms was 9%, 95% CI (3-17), I2=97%. Mean/median age, coronary artery disease, hypertension, diabetes, concomitant QT prolonging medications, ICU care, and severity of illness in the study populations explained between-studies heterogeneity.\nConclusions: Treatment of COVID-19 patients with CQ or HCQ is associated with a significant risk of drug-induced QT prolongation and relatively higher incidence of TdP/VT/cardiac arrest. Therefore, these agents should not be used routinely in the management of COVID-19 disease. COVID-19 patients who are treated with antimalarials for other indications should be adequately monitored."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":812,"end":822},"obj":"Phenotype"},{"id":"T2","span":{"begin":832,"end":846},"obj":"Phenotype"},{"id":"T3","span":{"begin":1029,"end":1040},"obj":"Phenotype"},{"id":"T4","span":{"begin":1224,"end":1236},"obj":"Phenotype"},{"id":"T5","span":{"begin":1558,"end":1572},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0011675"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0001695"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0011675"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0001695"}],"text":"The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.\nObjective: To systematically review the literature and estimate the risk of Chloroquine (CQ) and hydroxychloroquine (HCQ) cardiac toxicity in COVID-19 patients.\nMethods: We searched multiple data sources including PubMed/MEDLINE, Ovid Embase, Ovid EBM Reviews, Scopus, and Web of Science, and medrxiv.org from November 2019 through May 27, 2020. We included studies that enrolled COVID-19 patients treated with CQ or HCQ, with or without azithromycin and reported on cardiac toxicities. We performed a meta-analysis using the arcsine transformation of the different incidences.\nResults: A total of 19 studies with a total of 5652 patients were included. The pooled incidence of TdP arrhythmia or VT or cardiac arrest was 3 per 1000, 95% CI (0-21), I2=96%, 18 studies with 3725 patients. Among 13 studies of 4334 patients, the pooled incidence of discontinuation of CQ or HCQ due to prolonged QTc or arrhythmias was 5%, 95% CI (1-11), I2=98%. The pooled incidence of change in QTc from baseline of ≥ 60 ms or QTc ≥ 500 ms was 9%, 95% CI (3-17), I2=97%. Mean/median age, coronary artery disease, hypertension, diabetes, concomitant QT prolonging medications, ICU care, and severity of illness in the study populations explained between-studies heterogeneity.\nConclusions: Treatment of COVID-19 patients with CQ or HCQ is associated with a significant risk of drug-induced QT prolongation and relatively higher incidence of TdP/VT/cardiac arrest. Therefore, these agents should not be used routinely in the management of COVID-19 disease. COVID-19 patients who are treated with antimalarials for other indications should be adequately monitored."}